

L14

chain nodes :

1 4

ring/chain nodes :

2 3

chain bonds :

1-2 3-4

ring/chain bonds :

2-3

exact/norm bonds :

1-2 2-3 3-4

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS

10/734,545

=> d his

(FILE 'HOME' ENTERED AT 16:07:44 ON 19 FEB 2006)

FILE 'REGISTRY' ENTERED AT 16:07:49 ON 19 FEB 2006

L1 375 S SUCCINONITRILE  
L2 1 S SUCCINONITRILE/CN  
L3 STRUCTURE UPLOADED  
L4 50 S L3  
L5 66602 S 5-7/SZ  
L6 2228 S C3N2-C5N2/EA

FILE 'CAPLUS' ENTERED AT 16:11:41 ON 19 FEB 2006

L7 2546 S L1  
L8 1465 S L6  
L9 2 S L7 AND L8

FILE 'REGISTRY' ENTERED AT 16:12:33 ON 19 FEB 2006

L10 3703 S L3 SSS FUL

FILE 'CAPLUS' ENTERED AT 16:12:41 ON 19 FEB 2006

L11 4057 S L10  
L12 3 S L8 AND L11  
L13 1 S L12 NOT L9

FILE 'REGISTRY' ENTERED AT 16:15:13 ON 19 FEB 2006

L14 STRUCTURE UPLOADED  
L15 50 S L14  
L16 41797 S L14 SSS FUL

FILE 'CAPLUS' ENTERED AT 16:15:52 ON 19 FEB 2006

L17 24741 S L16  
L18 8 S L8 AND L17

=> d ibib abs hitstr total

10/734,545


~~IN~~ ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2006:99766 CAPLUS  
TITLE: STAT3 decoy oligonucleotides and use in the treatment  
of cancer  
INVENTOR(S): Grandis, Jennifer, Rubin; Johnson, Daniel, E.; Leong,  
Paul  
PATENT ASSIGNEE(S): University of Pittsburgh - Of the Commonwealth System  
of Higher Education, USA  
SOURCE: PCT Int. Appl., 67 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006012625	A2	20060202	WO 2005-US26361	20050722
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2004-590747P P 20040722  
AB A composition is provided that is useful in treating cancers in which STAT3 is activated, such as squamous cell carcinomas including squamous cell carcinoma of the head and neck. The composition comprises an effective amount of  
a STAT3 decoy and a pharmaceutically acceptable carrier. Also provided are methods of treating such cancers and methods of modulating STAT3 transcriptional activation in a cell.  
IT INDEXING IN PROGRESS  
IT 53910-25-1, Pentostatin 109511-58-2  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(STAT3 decoy oligonucleotides and use in treatment of cancer)  
RN 53910-25-1 CAPLUS  
CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy- $\beta$ -D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/734,545



RN 109511-58-2 CAPLUS


CN Butanedinitrile, bis[amino[(2-aminophenyl)thio]methylene] - (9CI) (CA  
INDEX NAME)



10/734,545

L18 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 2004:759869 CAPLUS  
DOCUMENT NUMBER: 141:243771  
TITLE: Process for the stereoselective synthesis of  
pentostatin aglycon and pentostatin via cyclization of  
dinitrile derivatives with amines  
INVENTOR(S): Sourena, Nadji; Smoot, James; Sampath, Umashanker  
PATENT ASSIGNEE(S): USA  
SOURCE: U.S. Pat. Appl. Publ., 21 pp.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004181052	A1	20040916	US 2003-734545	20031212
PRIORITY APPLN. INFO.:			US 2002-432380P	P 20021212
OTHER SOURCE(S):	MARPAT	141:243771		
GI				



I

AB A novel, scalable and improved process for preparing pentostatin and its analogs via stereoselective cyclization is disclosed. The method comprises the diastereospecific synthesis of the nucleobase from com. available L-dialkyl tartrate. Cyclization of dinitrile derivs., e.g. I, with a number of amines, e. g. allylamine, was performed to examine the practicality of the formation of the imidazole ring via the nucleophilic addition of an amino group to an electrophilic cyano functionality.


IT 749917-70-2P 749917-71-3P 749917-79-1P  
RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(process for stereoselective synthesis of pentostatin aglycon and pentostatin via cyclization of dinitrile derivs. with amines)

RN 749917-70-2 CAPLUS

CN Carbamic acid, [(1S,2S)-1,2-dicyano-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734,545



RN 749917-71-3 CAPLUS

CN Butanedinitrile, 2-amino-3-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-, (2S,3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 749917-79-1 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine, 8-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-, 3,6,7,8-tetrahydro-6-(3-nitrobenzoyl)-3-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 749917-72-4P 749917-81-5P

RL: IMF (Industrial manufacture); SPN (Synthetic preparation); PREP (Preparation)


(process for stereoselective synthesis of pentostatin aglycon and pentostatin via cyclization of dinitrile derivs. with amines)

RN 749917-72-4 CAPLUS

10/734,545

CN Methanimidic acid, N-[(1S,2S)-1,2-dicyano-2-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]ethyl]-, ethyl ester, (1E)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.  
Double bond geometry as shown.



RN 749917-81-5 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine, 8-[[[(1,1-dimethylethyl)diphenylsilyl]oxy]-3,4,7,8-tetrahydro-3-(phenylmethyl)-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L18 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:33978 CAPLUS  
 DOCUMENT NUMBER: 140:94236  
 TITLE: Preparation of ring-expanded nucleosides and nucleotides as virucides and bactericides  
 INVENTOR(S): Hosmane, Ramachandra S.; Sood, Ramesh K.  
 PATENT ASSIGNEE(S): Nabi, USA; University of Maryland Baltimore County  
 SOURCE: U.S., 51 pp.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6677310	B1	20040113	US 1999-295303	19990421
US 2004077564	A1	20040422	US 2003-679429	20031007
PRIORITY APPLN. INFO.:			US 1994-268570	B2 19940706
			US 1995-518278	A3 19950823
			US 1998-96614	B1 19980612
			US 1999-290615	B2 19990413
			US 1999-295303	A3 19990421

OTHER SOURCE(S): MARPAT 140:94236  
 GI



AB The present invention relates to compns. comprising analogs of purine nucleosides containing a ring-expanded ("fat") heterocyclic ring, in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivs. of such compns., as well as methods of use thereof. In particular, these compns. may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS), hepatitis, Epstein-Barr and cytomegalovirus. The present invention relates to compns. comprising analogs of purine nucleosides containing a ring-expanded ("fat") heterocyclic ring, I (R1, R3, R5 = independently NH, NH2, O, OH, S, SH, NH-alkyl, N-alkyl, O-alkyl, S-alkyl, NH-aryl, O-aryl, S-aryl; R2, R4, R7, R8 = independently, H, alkyl, substituted Ph, heterocycle, aralkyl; R6 = H, alkyl, Ph, substituted Ph, heterocycle, aralkyl, glycosyl; U, X, Y, Z, W, J, K, L = C, N) in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivs. of such compns., as well as methods of use thereof. In particular, these compns. may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS) and hepatitis.

6-Amino-6-methoxycarbonyl-4,5,7,8-tetrahydro-6H-imidazo[4,5,e]-[1,4]-diazepine-5,8-dione was prepared as adenosine deaminase and guanase inhibitor and tested for its anti-retroviral and antibacterial activities.

IT 155568-35-7P 155568-37-9P 155568-38-0P

159530-81-1P 159530-82-2P 162009-82-7P

169317-86-6P 169317-87-7P 216988-27-1P


224789-90-6P 244195-63-9P 398127-00-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ring-expanded nucleosides and as virucides and bactericides)


RN 155568-35-7 CAPLUS

CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 3,4,6,7-tetrahydro-3,4,7-tris(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 155568-37-9 CAPLUS

CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 2-bromo-3,4,6,7-tetrahydro-3,4-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 155568-38-0 CAPLUS


CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 2-bromo-3,4,6,7-tetrahydro-3,4,7-tris(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 159530-81-1 CAPLUS


10/734,545

CN Imidazo[4,5-e][1,4]diazepine-6-carboxylic acid, 6-amino-1,4,5,6,7,8-hexahydro-5,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 159530-82-2 CAPLUS


CN Imidazo[4,5-e][1,4]diazepine-6-carboxylic acid, 1,4,5,6,7,8-hexahydro-6-methoxy-5,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 162009-82-7 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169317-86-6 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-5(1H)-one, 4,6,7,8-tetrahydro-8-hydroxy-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/734,545




RN 169317-87-7 CAPLUS  
CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 1,4,6,7-tetrahydro-6-hydroxy-  
(9CI) (CA INDEX NAME)



RN 216988-27-1 CAPLUS  
CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1- $\beta$ -D-  
ribofuranosyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 224789-90-6 CAPLUS  
CN Imidazo[4,5-e][1,3]diazepine-4,8(1H,5H)-dione, 6-amino-1- $\beta$ -D-  
ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734,545



RN 244195-63-9 CAPLUS


CN Imidazo[4,5-e][1,3]diazepine-4,6-diamine, 1,8-dihydro-1-[5-O-  
[hydroxy[(hydroxy(phosphonooxy)phosphinyl)oxy]phosphinyl]-β-D-  
ribofuranosyl]-8-imino- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 398127-00-9 CAPLUS

CN Ethanol, 2-[(6,8-diamino-4-iminoimidazo[4,5-e][1,3]diazepin-1(4H)-  
yl)methoxy]- (9CI) (CA INDEX NAME)



IT 1122-28-7, 4,5-Dicyanoimidazole


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of ring-expanded nucleosides and as virucides and bactericides)

RN 1122-28-7 CAPLUS


CN 1H-Imidazole-4,5-dicarbonitrile (9CI) (CA INDEX NAME)

10/734,545




IT 94619-73-5P 123124-90-3P 139173-33-4P  
139173-34-5P 139173-35-6P 139173-36-7P  
139173-38-9P 162009-80-5P 162009-81-6P  
169317-84-4P 169317-88-8P 169317-91-3P  
169317-92-4P 216988-26-0P 216988-28-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of ring-expanded nucleosides and as virucides and bactericides)  
RN 94619-73-5 CAPLUS  
CN 1H-Imidazole-4,5-dicarbonitrile, 1-(2,3,5-tri-O-benzoyl-β-D-  
ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 123124-90-3 CAPLUS  
CN 1H-Imidazole-4,5-dicarbonitrile, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 139173-33-4 CAPLUS  
CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 3,4,6,7-tetrahydro-3-  
(phenylmethyl)- (9CI) (CA INDEX NAME)

10/734,545



RN 139173-34-5 CAPLUS


CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 139173-35-6 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 3,4,6,7-tetrahydro-3-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139173-36-7 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro-1-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734,545



RN 139173-38-9 CAPLUS


CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162009-80-5 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,6-diamine, 1,8-dihydro-8-imino-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 162009-81-6 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/734,545



RN 169317-84-4 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino- (9CI) (CA INDEX NAME)



RN 169317-88-8 CAPLUS


CN Methanesulfonic acid, trifluoro-, compd. with 1,6-dihydro-6-imino-1-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)imidazo[4,5-e][1,3]diazepine-4,8-diamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 162009-81-6

CMF C32 H27 N7 O7


Absolute stereochemistry.




CM 2

10/734,545


CRN 1493-13-6  
CMF C H F3 O3 S



RN 169317-91-3 CAPLUS  
CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 3,4,6,7-tetrahydro-6-methoxy-3,4-bis(phenylmethyl) - (9CI) (CA INDEX NAME)




RN 169317-92-4 CAPLUS  
CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 3,4,6,7-tetrahydro-6-hydroxy-3,4-bis(phenylmethyl) - (9CI) (CA INDEX NAME)



RN 216988-26-0 CAPLUS  
CN Imidazo[4,5-e][1,3]diazepine-4,8(1H,5H)-dione, 6-amino-, monohydrochloride (9CI) (CA INDEX NAME)

10/734,545




● HCl

RN 216988-28-2 CAPLUS

CN 1H-Imidazole-4,5-dicarbonitrile, 1-β-D-ribofuranosyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L18 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2000:741924 CAPLUS  
 DOCUMENT NUMBER: 133:305586  
 TITLE: Methods of inducing cancer cell death and tumor regression  
 INVENTOR(S): Bishop, Walter R.; Brassard, Diana L.; Nagabhushan, Tattanahalli L.  
 PATENT ASSIGNEE(S): Schering Corporation, USA  
 SOURCE: PCT Int. Appl., 84 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000061145	A1	20001019	WO 2000-US9124	20000406
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 6316462	B1	20011113	US 1999-289255	19990409
CA 2364675	AA	20001019	CA 2000-2364675	20000406
EP 1165078	A1	20020102	EP 2000-921765	20000406
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
BR 2000009670	A	20020115	BR 2000-9670	20000406
JP 2003529540	T2	20031007	JP 2000-610478	20000406
NZ 514628	A	20040130	NZ 2000-514628	20000406
AU 783177	B2	20050929	AU 2000-42041	20000406
ZA 2001008258	A	20030108	ZA 2001-8258	20011008
PRIORITY APPLN. INFO.:			US 1999-289255	A 19990409
			WO 2000-US9124	W 20000406
AB	Methods are provided for treating cancer, comprising administering (1) a farnesyl protein transferase inhibitor in conjunction with (2) an addnl. Ras signaling pathway inhibitor to induce cancer cell death and tumor regression.			
IT	53910-25-1, Pentostatin 109511-58-2, U0126 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods of inducing cancer cell death and tumor regression with farnesyl protein transferase inhibitors in conjunction with Ras signaling pathway inhibitors and use of other antitumor agents)			
RN	53910-25-1 CAPLUS			
CN	Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)-(9CI) (CA INDEX NAME)			


Absolute stereochemistry.

10/734,545



RN 109511-58-2 CAPLUS

CN Butanedinitrile, bis[amino[(2-aminophenyl)thio]methylene] - (9CI) (CA  
INDEX NAME)



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


10/734,545

L18 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

504  
37  
ACCESSION NUMBER: 1998:785657 CAPLUS  
DOCUMENT NUMBER: 130:38644  
TITLE: Preparation of ring-expanded nucleosides and  
nucleotides as virucides and bactericides  
INVENTOR(S): Hosmane, Ramachandra; Burns, Barry  
PATENT ASSIGNEE(S): University of Maryland, USA; Nabi  
SOURCE: U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 268,570,  
abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5843912	A	19981201	US 1995-518278	19950823
US 2004077564	A1	20040422	US 2003-679429	20031007
PRIORITY APPLN. INFO.:			US 1994-268570	B2 19940706
			US 1995-518278	A3 19950823
			US 1998-96614	B1 19980612
			US 1999-290615	B2 19990413
			US 1999-295303	A3 19990421

OTHER SOURCE(S): MARPAT 130:38644  
GI



AB The present invention relates to compns. comprising analogs of purine nucleosides containing a ring-expanded ("fat") heterocyclic ring, I (R1, R3, R5 = independently NH, NH2, O, OH, S, SH. NH-alkyl, N-alkyl, O-alkyl, S-alkyl, NH-aryl, O-aryl, S-aryl; R2, R4, R7, R8 = independently, H, alkyl, substituted Ph, heterocycle, aralkyl; R6 = H, alkyl, Ph, substituted Ph, heterocycle, aralkyl, glycosyl, ; U, X, Y, Z, W, J, K, L = C, N) in place of purine, and an unmodified or modified sugar residue, pharmaceutically acceptable derivs. of such compns., as well as methods of use thereof. In particular, these compns. may be utilized in the treatment of certain cancers, bacterial, fungal, parasitic, and viral infections, including, but not limited to, Acquired Immunodeficiency Syndrome (AIDS) and hepatitis. 6-Amino-6-methoxycarbonyl-4,5,7,8-tetrahydro-6H-imidazo[4,5,e]-[1,4]-diazepine-5,8-dione was prepared as adenosine deaminase and guanase inhibitor and tested for its anti-retroviral and antibacterial activities.

IT 159530-81-1P 159530-82-2P 162009-82-7P

169317-86-6P 169317-87-7P 216988-27-1P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological

10/734,545

study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);  
BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of ring-expanded nucleosides and as virucides and bactericides)


RN 159530-81-1 CAPLUS

CN Imidazo[4,5-e][1,4]diazepine-6-carboxylic acid, 6-amino-1,4,5,6,7,8-  
hexahydro-5,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 159530-82-2 CAPLUS


CN Imidazo[4,5-e][1,4]diazepine-6-carboxylic acid, 1,4,5,6,7,8-hexahydro-6-  
methoxy-5,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 162009-82-7 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-β-D-  
ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 169317-86-6 CAPLUS

CN Imidazo[4,5-d][1,3]diazepin-5(1H)-one, 4,6,7,8-tetrahydro-8-hydroxy-1-  
β-D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/734,545



RN 169317-87-7 CAPLUS


CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 1,4,6,7-tetrahydro-6-hydroxy-  
(9CI) (CA INDEX NAME)



RN 216988-27-1 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-beta-D-  
ribofuranosyl-, dihydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 1122-28-7, 4,5-Dicyanoimidazole


RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of ring-expanded nucleosides and as virucides and bactericides)

RN 1122-28-7 CAPLUS


CN 1H-Imidazole-4,5-dicarbonitrile (9CI) (CA INDEX NAME)

10/734,545




IT 94619-73-5P 123124-90-3P 139173-33-4P  
139173-34-5P 139173-35-6P 139173-36-7P  
139173-38-9P 162009-80-5P 162009-81-6P  
169317-84-4P 169317-88-8P 169317-91-3P  
169317-92-4P 216988-26-0P 216988-28-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of ring-expanded nucleosides and as virucides and bactericides)  
RN 94619-73-5 CAPLUS  
CN 1H-Imidazole-4,5-dicarbonitrile, 1-(2,3,5-tri-O-benzoyl-β-D-  
ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 123124-90-3 CAPLUS  
CN 1H-Imidazole-4,5-dicarbonitrile, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 139173-33-4 CAPLUS  
CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 3,4,6,7-tetrahydro-3-  
(phenylmethyl)- (9CI) (CA INDEX NAME)

10/734,545



RN 139173-34-5 CAPLUS


CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 139173-35-6 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 3,4,6,7-tetrahydro-3-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139173-36-7 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/734,545



RN 139173-38-9 CAPLUS


CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 162009-80-5 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,6-diamine, 1,8-dihydro-8-imino-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 162009-81-6 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

10/734,545



RN 169317-84-4 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino- (9CI) (CA INDEX NAME)



RN 169317-88-8 CAPLUS


CN Methanesulfonic acid, trifluoro-, compd. with 1,6-dihydro-6-imino-1-(2,3,5-tri-O-benzoyl-beta-D-ribofuranosyl)imidazo[4,5-e][1,3]diazepine-4,8-diamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 162009-81-6

CMF C32 H27 N7 O7


Absolute stereochemistry.




CM 2

10/734,545


CRN 1493-13-6  
CMF C H F3 O3 S



RN 169317-91-3 CAPLUS  
CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 3,4,6,7-tetrahydro-6-methoxy-3,4-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 169317-92-4 CAPLUS  
CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 3,4,6,7-tetrahydro-6-hydroxy-3,4-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 216988-26-0 CAPLUS  
CN Imidazo[4,5-e][1,3]diazepine-4,8(1H,5H)-dione, 6-amino-, monohydrochloride (9CI) (CA INDEX NAME)

10/734,545




● HCl

RN 216988-28-2 CAPLUS

CN 1H-Imidazole-4,5-dicarbonitrile, 1-β-D-ribofuranosyl- (9CI) (CA  
INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/734,545

L18 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:878823 CAPLUS

DOCUMENT NUMBER: 123:286534

TITLE: Preparation of ring-expanded bases, nucleosides and nucleotides as virucides, bactericides, fungicides, and parasiticides.

INVENTOR(S): Burns, Barry; Hosmane, Ramachandra

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 84 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9509175	A1	19950406	WO 1994-US10905	19940929
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LT, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, UZ, VN				
RW: KE, MW, SD, SZ, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2173116	AA	19950406	CA 1994-2173116	19940929
AU 9478445	A1	19950418	AU 1994-78445	19940929
EP 724587	A1	19960807	EP 1994-929358	19940929
EP 724587	B1	20020904		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
EP 1227103	A2	20020731	EP 2002-1587	19940929
EP 1227103	A3	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 223428	E	20020915	AT 1994-929358	19940929
PT 724587	T	20030131	PT 1994-929358	19940929
ES 2182847	T3	20030316	ES 1994-929358	19940929
PRIORITY APPLN. INFO.:			US 1993-128212	A 19930929
			EP 1994-929358	A3 19940929
			WO 1994-US10905	W 19940929
OTHER SOURCE(S):			MARPAT 123:286534	
GI				



AB Title compds. [I; R1, R3, R5 = NH, NH2, O, OH, S, SH, alkoxy, alkylthio, alkylamino, alkylimino, (substituted) aryloxy, arylamino, arylthio,

glycosylamino, glycosylimino, etc.; R2, R4, R6, R7, R8 = H, alkyl, (substituted) aryl, aralkyl, glycosyl, etc.; U, X, Y, Z, W, J, K, L = C, N, O, P, S; a = 0, 1] and related compds., were prepared Thus, 4,5-dicyanoimidazole, 1-O-acetyl-2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranose, hexamethyldisilazane, Me3SiCl, and F3CSO3H were stirred in MeCN in an ice water bath to give 94% 1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)-4,5-dicyanoimidazole. The latter was refluxed overnight with guanidine hydrochloride and NaOMe in MeOH to give 40% 4,6,8-triimino-1- $\beta$ -D-ribofuranosylimidazo[4,5-e][1,3]diazepine. The latter inhibited adenosine deaminase with  $K_i = 3.85 \cdot 10^{-4} + 10^{-4}$  M.

IT 159530-81-1P 159530-82-2P 162009-80-5P


162009-82-7P 169317-84-4P 169317-85-5P

169317-86-6P 169317-87-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of ring-expanded bases, nucleosides and nucleotides as virucides, bactericides, fungicides, and parasitocides)


RN 159530-81-1 CAPLUS

CN Imidazo[4,5-e][1,4]diazepine-6-carboxylic acid, 6-amino-1,4,5,6,7,8-hexahydro-5,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 159530-82-2 CAPLUS


CN Imidazo[4,5-e][1,4]diazepine-6-carboxylic acid, 1,4,5,6,7,8-hexahydro-6-methoxy-5,8-dioxo-, methyl ester (9CI) (CA INDEX NAME)



RN 162009-80-5 CAPLUS


CN Imidazo[4,5-e][1,3]diazepine-4,6-diamine, 1,8-dihydro-8-imino-1-(phenylmethyl)- (9CI) (CA INDEX NAME)

10/734,545




RN 162009-82-7 CAPLUS  
CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 169317-84-4 CAPLUS  
CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino- (9CI) (CA INDEX NAME)



RN 169317-85-5 CAPLUS  
CN Imidazo[4,5-e][1,3]diazepine-4,8(1H,5H)-dione, 6-amino- (9CI) (CA INDEX NAME)




10/734,545

RN 169317-86-6 CAPLUS


CN Imidazo[4,5-d][1,3]diazepin-5(1H)-one, 4,6,7,8-tetrahydro-8-hydroxy-1- $\beta$ -D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 169317-87-7 CAPLUS

CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 1,4,6,7-tetrahydro-6-hydroxy- (9CI) (CA INDEX NAME)



IT 139173-35-6P


RL: BYP (Byproduct); PREP (Preparation)

(preparation of ring-expanded bases, nucleosides and nucleotides as virucides, bactericides, fungicides, and parasitocides)

RN 139173-35-6 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 3,4,6,7-tetrahydro-3-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 1122-28-7, 4,5-Dicyanoimidazole


RL: RCT (Reactant); RACT (Reactant or reagent)

10/734,545

(preparation of ring-expanded bases, nucleosides and nucleotides as  
virucides, bactericides, fungicides, and parasiticides)

RN 1122-28-7 CAPLUS

CN 1H-Imidazole-4,5-dicarbonitrile (9CI) (CA INDEX NAME)



IT 94619-73-5P 123124-90-3P 139173-33-4P

139173-34-5P 139173-36-7P 139173-38-9P

169317-88-8P 169317-91-3P 169317-92-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)

(preparation of ring-expanded bases, nucleosides and nucleotides as  
virucides, bactericides, fungicides, and parasiticides)

RN 94619-73-5 CAPLUS


CN 1H-Imidazole-4,5-dicarbonitrile, 1-(2,3,5-tri-O-benzoyl-β-D-  
ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 123124-90-3 CAPLUS


CN 1H-Imidazole-4,5-dicarbonitrile, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 139173-33-4 CAPLUS


CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 3,4,6,7-tetrahydro-3-  
(phenylmethyl)- (9CI) (CA INDEX NAME)

10/734,545



RN 139173-34-5 CAPLUS


CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro- (9CI) (CA INDEX NAME)



RN 139173-36-7 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 139173-38-9 CAPLUS

CN Imidazo[4,5-d][1,3]diazepine-5,8-dione, 1,4,6,7-tetrahydro-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

10/734,545



RN 169317-88-8 CAPLUS


CN Methanesulfonic acid, trifluoro-, compd. with 1,6-dihydro-6-imino-1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)imidazo[4,5-e][1,3]diazepine-4,8-diamine (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 162009-81-6

CMF C32 H27 N7 O7


Absolute stereochemistry.



CM 2

CRN 1493-13-6


CMF C H F3 O3 S



RN 169317-91-3 CAPLUS


CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 3,4,6,7-tetrahydro-6-methoxy-3,4-bis(phenylmethyl)- (9CI) (CA INDEX NAME)

10/734,545



RN 169317-92-4 CAPLUS

CN Imidazo[4,5-e][1,4]diazepine-5,8-dione, 3,4,6,7-tetrahydro-6-hydroxy-3,4-bis(phenylmethyl)- (9CI) (CA INDEX NAME)



L18 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1995:273394 CAPLUS

DOCUMENT NUMBER: 122:214413

TITLE: A short synthesis of a novel ring-expanded purine and its nucleoside analog containing the imidazo[4,5-e][1,3]diazepine ring skeleton with multiple amino substituents attached to the 7-membered ring

AUTHOR(S): Wang, Lijuan; Bhan, Anila; Hosmane, Ramachandra S.; Guiles, R. D.

CORPORATE SOURCE: Dep. of Chemistry and Biochemistry, Univ. of Maryland Baltimore County, Baltimore, MD, 21228, USA

SOURCE: Nucleosides & Nucleotides (1994), 13(10), 2307-20  
CODEN: NUNUD5; ISSN: 0732-8311


PUBLISHER: Dekker

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 122:214413

GI



AB The synthesis of 4,6,8-triaminoimidazo[4,5-e][1,3]diazepine (I) and its nucleoside analog (II) are reported. The heterocycle was prepared in a single step by condensation of 4,5-dicyanoimidazole with guanidine. The 5,7-fused ring structure of I was distinguished from the other possible 5:5-fused isomer by preparing the 15N-labeled heterocycle (1\*) and exploring its 15N-1H coupling patterns in both 1H and 15N NMR spectra. These spectral patterns also enabled establishment of the triamino tautomeric form of I as assigned. Compound I, a novel ring-expanded ("fat") analog of purine, is anticipated to be planar and aromatic as predicted by mol. modeling. The 1-benzyl analog (III), a protocol for the ribosyl analog II, was similarly prepared from 1-benzyl-4,5-dicyanoimidazole. The nucleoside II was prepared by the modified Vorbrueggen ribosylation of I.

The position of ribosylation was unequivocally established by an unambiguous synthesis of II from condensation of 1-(2',3',5'-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)-4,5-dicyanoimidazole (IV) with guanidine in a solution of sodium methoxide in methanol. The nucleoside IV was prepared by the Vorbrueggen ribosylation of 4,5-dicyanoimidazole.

IT 94619-73-5P 123124-90-3P 162009-79-2P

162009-80-5P 162009-81-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(a short synthesis of a novel ring-expanded aminopurine and nucleoside analog)

RN 94619-73-5 CAPLUS


CN 1H-Imidazole-4,5-dicarbonitrile, 1-(2,3,5-tri-O-benzoyl- $\beta$ -D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 123124-90-3 CAPLUS

CN 1H-Imidazole-4,5-dicarbonitrile, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 162009-79-2 CAPLUS


CN Imidazo[4,5-e][1,3]diazepine-4,6,8-triamine (9CI) (CA INDEX NAME)



RN 162009-80-5 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,6-diamine, 1,8-dihydro-8-imino-1-(phenylmethyl)- (9CI) (CA INDEX NAME)


10/734,545



RN 162009-81-6 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 162009-82-7P 162009-83-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(a short synthesis of a novel ring-expanded aminopurine and nucleoside analog)

RN 162009-82-7 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,8-diamine, 1,6-dihydro-6-imino-1-β-D-ribofuranosyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 162009-83-8 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,6,8-triamine-N6,5,7-15N3 (9CI) (CA INDEX NAME)

10/734,545




IT 1122-28-7, 4,5-Dicyanoimidazole  
RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction with guanidine)  
RN 1122-28-7 CAPLUS  
CN 1H-Imidazole-4,5-dicarbonitrile (9CI) (CA INDEX NAME)



10/734,545

118 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN  
ACCESSION NUMBER: 1990:198331 CAPLUS  
DOCUMENT NUMBER: 112:198331  
TITLE: Imidazo[4,5-e][1,3]diazepine-4,6-dione. A novel  
xanthine analog  
AUTHOR(S): Bridson, Peter K.; Lambert, Steven J.  
CORPORATE SOURCE: Dep. Chem., Memphis State Univ., Memphis, TN, 38152,  
USA  
SOURCE: Journal of the Chemical Society, Perkin Transactions  
1: Organic and Bio-Organic Chemistry (1972-1999)  
(1990), (1), 173-5  
CODEN: JCPRB4; ISSN: 0300-922X  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 112:198331  
GI




AB Imidazolyldicarbonylaminomethylimidazolecarboxamide I was treated with Ac<sub>2</sub>O in anhydrous dioxan to give 40% benzyldihydroimidazodiazepinedione II (R = PhCH), which on hydrogenolysis gave II (R = H).

IT **126921-91-3P**  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and debenzylation of)

RN 126921-91-3 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,6(1H,5H)-dione, 7,8-dihydro-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




IT **126921-83-3P**  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 126921-83-3 CAPLUS

CN Imidazo[4,5-e][1,3]diazepine-4,6(1H,5H)-dione, 7,8-dihydro- (9CI) (CA INDEX NAME)

10/734,545



IT 123124-90-3, 1-Benzyl-4,5-dicyanoimidazole

RL: RCT (Reactant); RACT (Reactant or reagent)  
(reaction of, with ethoxide)

RN 123124-90-3 CAPLUS

CN 1H-Imidazole-4,5-dicarbonitrile, 1-(phenylmethyl)- (9CI) (CA INDEX NAME)

